FANCD2OS

Summary

FANCD2OS (FANCD2 opposite strand, HGNC:28623) is a protein-coding gene on chromosome 3p25.3, encoding FANCD2 opposite strand protein (Q96PS1). Reduces testosterone levels by inhibiting steroidogenic enzymes and by promoting apoptosis in Leydig cells.

This gene encodes a conserved protein of unknown function.

Source: NCBI Gene 115795 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 97 total — 4 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_001164839

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28623
Approved symbol	FANCD2OS
Name	FANCD2 opposite strand
Location	3p25.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC40179
Ensembl gene	ENSG00000163705
Ensembl biotype	protein_coding
OMIM	621082
Entrez	115795

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding_CDS_not_defined, 3 protein_coding

ENST00000431315, ENST00000436517, ENST00000450616, ENST00000450660, ENST00000453223, ENST00000524279

RefSeq mRNA: 2 — MANE Select: NM_001164839 NM_001164839, NM_173472

CCDS: CCDS2596

Canonical transcript exons

ENST00000450660 — 2 exons

Exon	Start	End
ENSE00001644655	10108015	10108255
ENSE00002092506	10103937	10104782

Expression profiles

Bgee: expression breadth ubiquitous, 120 present calls, max score 95.73.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1185 / max 115.9288, expressed in 4 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41019	0.1086	4
41020	0.0098	3

Top tissues by expression

230 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	95.73	gold quality
right testis	UBERON:0004534	95.41	gold quality
testis	UBERON:0000473	92.08	gold quality
pancreatic ductal cell	CL:0002079	92.06	silver quality
sperm	CL:0000019	86.58	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.61	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.94	gold quality
adult organism	UBERON:0007023	79.72	gold quality
ileal mucosa	UBERON:0000331	74.75	silver quality
myocardium	UBERON:0002349	70.48	gold quality
cardiac muscle of right atrium	UBERON:0003379	69.83	gold quality
left ventricle myocardium	UBERON:0006566	69.58	gold quality
deltoid	UBERON:0001476	66.65	gold quality
upper arm skin	UBERON:0004263	65.32	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	64.20	gold quality
quadriceps femoris	UBERON:0001377	63.99	gold quality
upper leg skin	UBERON:0004262	62.17	silver quality
vastus lateralis	UBERON:0001379	61.97	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	61.54	gold quality
tendon of biceps brachii	UBERON:0008188	60.93	gold quality
heart right ventricle	UBERON:0002080	60.70	gold quality
nasal cavity epithelium	UBERON:0005384	60.07	gold quality
biceps brachii	UBERON:0001507	59.63	gold quality
superficial temporal artery	UBERON:0001614	58.76	gold quality
gingival epithelium	UBERON:0001949	55.72	gold quality
lateral globus pallidus	UBERON:0002476	54.73	gold quality
skeletal muscle tissue	UBERON:0001134	54.68	gold quality
gingiva	UBERON:0001828	54.50	gold quality
parotid gland	UBERON:0001831	54.45	gold quality
muscle tissue	UBERON:0002385	54.40	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.21

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

34 targeting FANCD2OS, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-580-3P	99.67	69.23	1841
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-122B-5P	99.46	70.81	1457
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-5582-5P	99.27	71.42	1879
HSA-MIR-1911-5P	98.92	67.53	325
HSA-MIR-4450	98.26	68.35	725
HSA-MIR-3650	97.88	64.89	693
HSA-MIR-4433A-3P	97.75	62.82	1435
HSA-MIR-299-3P	97.73	66.67	773
HSA-MIR-4253	97.48	65.11	692
HSA-MIR-6862-5P	97.48	64.84	713
HSA-MIR-5192	96.89	63.35	879
HSA-MIR-4703-3P	96.68	68.61	545
HSA-MIR-4491	96.53	66.20	935
HSA-MIR-4657	96.53	66.57	895
HSA-MIR-4761-3P	96.27	66.26	524

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fancd2os	ENSMUSG00000033963
rattus_norvegicus	Fancd2os	ENSRNOG00000010177
rattus_norvegicus		ENSRNOG00000072822
rattus_norvegicus	Fancd2osl1	ENSRNOG00000077755
rattus_norvegicus		ENSRNOG00000085190
rattus_norvegicus		ENSRNOG00000088812

Protein

Protein identifiers

FANCD2 opposite strand protein — Q96PS1 (reviewed: Q96PS1)

Alternative names: Fanconi anemia group D2 protein opposite strand transcript protein

All UniProt accessions (2): Q96PS1, H0YBI7

UniProt curated annotations — full annotation on UniProt →

Function. Reduces testosterone levels by inhibiting steroidogenic enzymes and by promoting apoptosis in Leydig cells.

Subcellular location. Cytoplasm.

RefSeq proteins (2): NP_001158311, NP_775743 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR027966	FANCD2OS	Family

Pfam: PF15124

UniProt features (1 total): chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96PS1-F1	61.31	0.15

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 59 (showing top): GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, CMYB_01, GOBP_NEGATIVE_REGULATION_OF_STEROID_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS, GOBP_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS, GOBP_REGULATION_OF_KETONE_METABOLIC_PROCESS, GOBP_STEROID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_KETONE_BIOSYNTHETIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_STEROID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_STEROID_METABOLIC_PROCESS

GO Biological Process (1): negative regulation of testosterone biosynthetic process (GO:2000225)

GO Molecular Function (0):

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of steroid biosynthetic process	1
testosterone biosynthetic process	1
negative regulation of small molecule metabolic process	1
regulation of testosterone biosynthetic process	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

320 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FANCD2OS	TRIML1	Q8N9V2	514
FANCD2OS	PRRT3	Q5FWE3	479
FANCD2OS	TATDN2	Q93075	446
FANCD2OS	CCDC152	Q4G0S7	443
FANCD2OS	CPNE9	Q8IYJ1	433
FANCD2OS	THUMPD3	Q9BV44	419
FANCD2OS	SSUH2	Q9Y2M2	419
FANCD2OS	SP2	Q02086	414
FANCD2OS	TMEM232	C9JQI7	390
FANCD2OS	LHFPL4	Q7Z7J7	380
FANCD2OS	RPUSD3	Q6P087	370
FANCD2OS	JAGN1	Q8N5M9	359
FANCD2OS	TTLL3	Q9Y4R7	354
FANCD2OS	NARS1	O43776	345
FANCD2OS	ERCC6L2	Q5T890	336

IntAct

4 interactions, top by confidence:

A	B	Type	Score
FANCD2OS	CNOT1	psi-mi:“MI:0914”(association)	0.530

BioGRID (25): MINK1 (Affinity Capture-MS), RQCD1 (Affinity Capture-MS), CNOT3 (Affinity Capture-MS), MAP4K4 (Affinity Capture-MS), TROAP (Affinity Capture-MS), CNOT10 (Affinity Capture-MS), FBRS (Affinity Capture-MS), BTG3 (Affinity Capture-MS), RNF219 (Affinity Capture-MS), KIAA0232 (Affinity Capture-MS), CNOT6 (Affinity Capture-MS), CNOT7 (Affinity Capture-MS), DYRK1A (Affinity Capture-MS), CNOT11 (Affinity Capture-MS), TNKS1BP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GTK4, A0JNL8, A2RU37, A4D1N5, B1A0U8, B1ANY3, F2Z398, G3V211, J3KSC0, J3QMY9, O14603, O93195, O95411, P03414, P0C7M3, P37200, P47939, P47940, P49671, P92561, Q02919, Q32KZ5, Q4G0G2, Q5SR53, Q5T0J3, Q5T6R2, Q66669, Q66HF0, Q6AWC8, Q6DGF6, Q6ZP68, Q6ZSR6, Q7L4S7, Q86UQ5, Q86Y29, Q8BGX4, Q8N326, Q8N4M7, Q8N6C7, Q8N769

Diamond homologs: Q32KZ5, Q96PS1, Q9D4K4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

97 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	2
Uncertain significance	52
Likely benign	24
Benign	10

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
1685811	NM_001018115.3(FANCD2):c.3777+1G>T	Pathogenic
2807269	NM_001018115.3(FANCD2):c.3693del (p.Phe1231fs)	Pathogenic
456559	NC_000003.12:g.(?10064723)(10149971_?)del	Pathogenic
929670	NM_001018115.3(FANCD2):c.3803G>A (p.Trp1268Ter)	Pathogenic
1345612	NC_000003.11:g.(?10132039)(10132856_?)del	Likely pathogenic
2744051	NM_001018115.3(FANCD2):c.3224+1G>C	Likely pathogenic

SpliceAI

2283 predictions. Top by Δscore:

Variant	Effect	Δscore
3:10081344:A:AG	acceptor_gain	1.0000
3:10081345:G:GT	acceptor_gain	1.0000
3:10081345:GT:G	acceptor_gain	1.0000
3:10081460:GCTTG:G	donor_gain	1.0000
3:10081461:CTTGG:C	donor_loss	1.0000
3:10081462:TTGG:T	donor_loss	1.0000
3:10081463:TGGT:T	donor_loss	1.0000
3:10081465:G:C	donor_loss	1.0000
3:10081465:G:GG	donor_gain	1.0000
3:10081466:T:TC	donor_loss	1.0000
3:10081467:AA:A	donor_loss	1.0000
3:10085811:GGA:G	acceptor_gain	1.0000
3:10088821:A:AG	acceptor_gain	1.0000
3:10088825:CAG:C	acceptor_loss	1.0000
3:10088826:A:AG	acceptor_gain	1.0000
3:10088826:A:G	acceptor_loss	1.0000
3:10088827:G:GT	acceptor_gain	1.0000
3:10088827:GT:G	acceptor_gain	1.0000
3:10088827:GTA:G	acceptor_gain	1.0000
3:10088827:GTAT:G	acceptor_gain	1.0000
3:10088827:GTATC:G	acceptor_gain	1.0000
3:10088949:AGGTA:A	donor_loss	1.0000
3:10088951:G:C	donor_loss	1.0000
3:10088952:T:G	donor_loss	1.0000
3:10090314:C:CA	acceptor_gain	1.0000
3:10090316:T:TA	acceptor_gain	1.0000
3:10090318:T:TA	acceptor_gain	1.0000
3:10081344:AGT:A	acceptor_gain	0.9900
3:10081345:GTG:G	acceptor_gain	0.9900
3:10081345:GTGT:G	acceptor_gain	0.9900

AlphaMissense

1149 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:10104397:A:C	F126L	0.984
3:10104397:A:T	F126L	0.984
3:10104399:A:G	F126L	0.984
3:10104470:A:T	V102D	0.975
3:10104270:A:G	C169R	0.972
3:10104321:A:G	C152R	0.969
3:10104308:A:G	L156P	0.966
3:10104398:A:G	F126S	0.966
3:10104466:A:C	F103L	0.966
3:10104466:A:T	F103L	0.966
3:10104468:A:G	F103L	0.966
3:10104720:A:G	W19R	0.966
3:10104720:A:T	W19R	0.966
3:10104305:C:G	R157P	0.965
3:10104262:A:C	F171L	0.962
3:10104262:A:T	F171L	0.962
3:10104264:A:G	F171L	0.962
3:10104274:T:A	K167N	0.960
3:10104274:T:G	K167N	0.960
3:10104285:C:G	A164P	0.954
3:10104756:A:G	W7R	0.954
3:10104756:A:T	W7R	0.954
3:10104296:A:G	L160P	0.952
3:10104275:T:A	K167I	0.951
3:10104488:A:T	L96H	0.951
3:10104290:A:G	L162P	0.949
3:10104279:A:C	Y166D	0.948
3:10104288:A:C	Y163D	0.945
3:10104488:A:G	L96P	0.941
3:10104401:G:T	A125D	0.939

dbSNP variants (sampled 300 via entrez): RS1000088984 (3:10095431 A>C), RS1000094692 (3:10103647 T>C), RS1000142282 (3:10108712 G>A), RS1000158209 (3:10106464 G>A), RS1000254003 (3:10085865 T>A), RS1000278037 (3:10106799 G>A,T), RS1000437618 (3:10094211 T>C), RS1000474147 (3:10107452 A>AT), RS1000704082 (3:10101524 G>A,T), RS1000881167 (3:10082400 C>T), RS1000992041 (3:10082147 A>G), RS1001077491 (3:10081282 C>A,T), RS1001129479 (3:10100783 A>G), RS1001285026 (3:10094769 G>A), RS1001355687 (3:10107444 C>G)

Disease associations

OMIM: gene MIM:621082 | disease phenotypes: MIM:227650, MIM:227646, MIM:193300, MIM:263400

GenCC curated gene-disease

Mondo (5): Fanconi anemia (MONDO:0019391), Fanconi anemia complementation group D2 (MONDO:0009214), hereditary breast ovarian cancer syndrome (MONDO:0003582), von Hippel-Lindau disease (MONDO:0008667), Chuvash polycythemia (MONDO:0009892)

Orphanet (4): Fanconi anemia (Orphanet:84), Hereditary breast and/or ovarian cancer syndrome (Orphanet:145), Chuvash erythrocytosis (Orphanet:238557), Von Hippel-Lindau disease (Orphanet:892)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002422_5	Alzheimer’s disease	2.000000e-06
GCST003264_1052	Post bronchodilator FEV1/FVC ratio	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004713	FEV/FVC ratio

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D005199	Fanconi Anemia	C15.378.050.085.080.280; C15.378.190.223.500.500.280; C16.320.077.280; C18.452.284.280
D061325	Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483; C04.588.322.455.431; C04.700.517; C12.050.351.500.056.630.705.431; C12.050.351.937.418.685.431; C12.100.250.056.630.705.431; C12.900.418.685.431; C16.320.700.517; C17.800.090.500.483; C19.344.410.431; C19.391.630.705.431
D006623	von Hippel-Lindau Disease	C10.562.925; C14.907.077.925; C16.131.077.245.750; C16.320.184.750
C563918	Erythrocytosis, Familial, 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	2
Arbutin	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

134 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02562170	PHASE4	COMPLETED	Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study
NCT06519786	PHASE3	UNKNOWN	Safety and Efficacy of Metformin for Treatment of Cytopenia in Children and Adolescents With Fanconi Anemia
NCT00673335	PHASE3	COMPLETED	Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation
NCT00685256	PHASE3	COMPLETED	Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
NCT03162276	PHASE3	UNKNOWN	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
NCT00000603	PHASE2	COMPLETED	Cord Blood Stem Cell Transplantation Study (COBLT)
NCT00001749	PHASE2	COMPLETED	Medical Treatment for Diamond Blackfan Anemia
NCT00004787	PHASE2	COMPLETED	Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
NCT00053989	PHASE2	COMPLETED	NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
NCT00084695	PHASE2	UNKNOWN	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
NCT00258427	PHASE2	COMPLETED	Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
NCT00453388	PHASE2	COMPLETED	Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia
NCT01071239	PHASE2	COMPLETED	Hematopoietic Stem Cell Transplant for Fanconi Anemia
NCT02143830	PHASE2	RECRUITING	HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
NCT02931071	PHASE2	COMPLETED	Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1
NCT03206086	PHASE2	ACTIVE_NOT_RECRUITING	Eltrombopag for People With Fanconi Anemia
NCT03398824	PHASE2	COMPLETED	Pilot Study of Metformin for Patients With Fanconi Anemia
NCT03476330	PHASE2	COMPLETED	Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
NCT03579875	PHASE2	RECRUITING	Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03600909	PHASE2	TERMINATED	A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
NCT04232085	PHASE2	RECRUITING	Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
NCT06045052	PHASE2	COMPLETED	Eltrombopag for Treatment of Fanconi Anemia
NCT00253539	PHASE2	COMPLETED	Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer
NCT00305695	PHASE2	COMPLETED	Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
NCT00321633	PHASE2	COMPLETED	Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
NCT01333748	PHASE2	COMPLETED	Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer
NCT01367639	PHASE2	COMPLETED	Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
NCT00001399	PHASE1	COMPLETED	Gene Therapy for the Treatment of Fanconi’s Anemia Type C
NCT00005896	PHASE1	UNKNOWN	Phase I Pilot Study of CD34 Enriched, Fanconi’s Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi’s Anemia
NCT00006127	PHASE1	UNKNOWN	Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi’s Anemia
NCT00093743	PHASE1	COMPLETED	Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
NCT00243399	PHASE1	COMPLETED	Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia
NCT00272857	PHASE1	COMPLETED	Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia
NCT00317876	PHASE1	COMPLETED	Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi’s Anemia
NCT00586274	PHASE1	TERMINATED	Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
NCT01331018	PHASE1	TERMINATED	Gene Therapy for Fanconi Anemia
NCT01720147	PHASE1	COMPLETED	Quercetin in Children With Fanconi Anemia; a Pilot Study
NCT01917708	PHASE1	COMPLETED	Bone Marrow Transplant With Abatacept for Non-Malignant Diseases
NCT00535119	PHASE1	COMPLETED	Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer
NCT00892736	PHASE1	COMPLETED	Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy